CA2259965A1 - Hiv envelope polypeptides and vaccine - Google Patents

Hiv envelope polypeptides and vaccine Download PDF

Info

Publication number
CA2259965A1
CA2259965A1 CA002259965A CA2259965A CA2259965A1 CA 2259965 A1 CA2259965 A1 CA 2259965A1 CA 002259965 A CA002259965 A CA 002259965A CA 2259965 A CA2259965 A CA 2259965A CA 2259965 A1 CA2259965 A1 CA 2259965A1
Authority
CA
Canada
Prior art keywords
thr
asn
ile
lys
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002259965A
Other languages
English (en)
French (fr)
Inventor
Phillip W. Berman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2259965A1 publication Critical patent/CA2259965A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002259965A 1996-07-08 1997-07-03 Hiv envelope polypeptides and vaccine Abandoned CA2259965A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67673796A 1996-07-08 1996-07-08
US08/676,737 1996-07-08

Publications (1)

Publication Number Publication Date
CA2259965A1 true CA2259965A1 (en) 1998-01-15

Family

ID=24715764

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002259965A Abandoned CA2259965A1 (en) 1996-07-08 1997-07-03 Hiv envelope polypeptides and vaccine

Country Status (13)

Country Link
US (1) US6090392A (enExample)
EP (1) EP0942988A1 (enExample)
JP (1) JP2000515368A (enExample)
AP (1) AP1282A (enExample)
AU (1) AU727107B2 (enExample)
CA (1) CA2259965A1 (enExample)
ID (1) ID17767A (enExample)
IL (2) IL127701A0 (enExample)
NZ (1) NZ333500A (enExample)
OA (1) OA10954A (enExample)
TW (1) TWI221846B (enExample)
WO (1) WO1998001564A1 (enExample)
ZA (1) ZA975889B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562347B1 (en) 1998-03-12 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Chemokine-tumor antigen fusion proteins as cancer vaccines
MXPA02007478A (es) 2000-02-04 2004-08-23 Univ Duke Vacuna contra el virus de inmunodeficiencia humana.
AU2001254567A1 (en) * 2000-05-02 2001-11-12 Simon Fraser University Polypeptides for use as a vaccine and/or treatment for hiv infection
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
WO2002022686A2 (en) 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
WO2002022687A2 (en) 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Viral chemokine-tumur antigen fusion proteins
US20060116325A1 (en) * 2001-02-15 2006-06-01 Oleg Chertov Methods and compositions for inhibiting hiv-coreceptor interactions
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
US7901690B2 (en) * 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
US20050025779A1 (en) * 2003-06-12 2005-02-03 Vaxgen, Inc. HIV-1 envelope glycoproteins having unusual disulfide structure
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
PL1692516T3 (pl) * 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
DK1805510T3 (da) * 2004-09-08 2012-04-30 Immunaid Pty Ltd Terapeutisk strategi til behandling af autoimmune og degenerative sygdomme
ES2610781T3 (es) * 2004-09-14 2017-05-03 Argos Therapeutics, Inc. Amplificación de patógenos independiente de la cepa y vacunas para estos
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
WO2009017743A2 (en) 2007-07-30 2009-02-05 Argos Therapeutics, Inc. Improved primers and probes for the amplification and detection of hiv gag, rev and nef polynucleotides
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
HUE026456T2 (en) 2009-05-27 2016-05-30 Biotempus Ltd Methods of treating diseases
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US9951106B2 (en) 2012-12-04 2018-04-24 University Of Maryland, Baltimore Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187041B1 (en) * 1984-12-24 1996-05-15 Genentech, Inc. Fusions of AIDS-related polypeptides
ES2102347T3 (es) * 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5116740A (en) * 1988-08-16 1992-05-26 Akzo N.V. Method for producing native hiv gp160
AU6523590A (en) * 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
CA2078545A1 (en) * 1990-04-03 1991-10-04 Timothy J. Gregory Hiv envelope polypeptides
EP0527760B1 (en) * 1990-04-03 1995-07-19 Genentech, Inc. Methods and compositions for vaccination against hiv
AU700371B2 (en) * 1993-06-07 1999-01-07 Genentech Inc. Hiv envelope polypeptides

Also Published As

Publication number Publication date
EP0942988A1 (en) 1999-09-22
ZA975889B (en) 1998-02-23
NZ333500A (en) 2000-09-29
US6090392A (en) 2000-07-18
JP2000515368A (ja) 2000-11-21
WO1998001564A1 (en) 1998-01-15
AU727107B2 (en) 2000-11-30
IL127701A (en) 2006-08-01
TWI221846B (en) 2004-10-11
ID17767A (id) 1998-01-22
IL127701A0 (en) 1999-10-28
OA10954A (en) 2001-10-25
AU3567797A (en) 1998-02-02
AP1282A (en) 2004-06-09
AP9901432A0 (en) 1999-03-31

Similar Documents

Publication Publication Date Title
CA2259965A1 (en) Hiv envelope polypeptides and vaccine
AU704309B2 (en) Antigenically-marked non-infectious retrovirus-like particles
US6080408A (en) Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
EP0904380B1 (en) Synthetic hiv genes
US20030229214A1 (en) Vaccines comprising synthetic genes
US6544752B1 (en) Anigenically-marked non-infectious retrovirus-like particles
JP2000516445A (ja) 合成遺伝子を含むワクチン
CA2369119A1 (en) Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
US7071322B2 (en) HIV envelope polynucleotides and immunogenic composition
US6121021A (en) Constitutive expression of non-infectious HIV-like particles
CA2338886C (en) Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
CA2135200C (en) Canine coronavirus s gene and uses therefor
US20100080818A1 (en) Expression and Characterization of HIV-1 Envelope Protein Associated with Broadly Cross Reactive Neutralizing Antibody Response
US20030087225A1 (en) Synthetic HIV genes
HK1046428A1 (zh) 1型人类免疫缺乏病毒(hiv-1)亚型间的基因组及其应用
HK1046428B (en) The genome of the hiv-1 inter-subtype (c/b') and use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued